Viatris Inc. Annual Report: A Year of Strategic Transformation Amidst Headwinds

Viatris Inc., a global pharmaceutical company with a diverse portfolio of branded and generic medicines, faced a challenging yet transformative year. Despite revenue declines, the company aggressively streamlined its business, reduced debt, and invested in future growth, positioning itself to become a more focused and agile specialty pharmaceutical leader.

1. Business Overview and Performance Snapshot

Viatris operates in a wide range of therapeutic areas, providing both established branded products (such as Lipitor, Norvasc, and EpiPen) and high-quality generic and biosimilar medicines. Last year was pivotal as the company advanced its "Viatris Way" strategy, concentrating on optimizing its product portfolio and allocating capital effectively.

Key Performance Highlights (2024 vs. 2023):

• Total Revenue: Decreased by 4.6% from $13.34 billion to $12.73 billion.
• Net Income (GAAP): Shifted from a $1.5 billion profit in 2023 to a net loss of $500 million in 2024, primarily due to costs from divestitures and asset impairments.
• Adjusted Net Income: Remained positive at $2.0 billion in 2024, down from $2.5 billion in 2023, reflecting underlying operational performance.
• Adjusted Earnings Per Share (EPS): $4.00 in 2024, compared to $5.00 in 2023.
• Free Cash Flow: Generated $1.8 billion in 2024, down from $2.5 billion in 2023, but still robust.

2. Detailed Financial Performance

Revenue declined broadly, affecting both branded and generic segments across all major geographic regions.

• Branded Products: Sales fell 4.6% from $7.71 billion to $7.355 billion. Key product performance included:
  • Lipitor: $1.05 billion (down from $1.1 billion)
  • Norvasc: $365 million (down from $380 million)
  • Lyrica: $315 million (down from $330 million)
  • EpiPen Auto-Injectors: $260 million (down from $270 million)
  • Viagra: $210 million (down from $220 million)
  • Creon: $155 million (down from $160 million)
  • Celebrex: $105 million (down from $110 million)
  • Several other products like Effexor, Zoloft, Xalabrands, Yupelri, Influvac, Dymista, Amitiza, and Xanax maintained stable sales of $50 million each.
• Generic Products: Sales decreased 4.5% from $5.63 billion to $5.375 billion. This segment continues to face significant pricing pressure and increased competition.

Non-cash charges, including goodwill impairment and restructuring costs from ongoing portfolio optimization, primarily drove the GAAP net loss. However, the company's ability to generate substantial adjusted net income and free cash flow highlights the profitability of its core operations.

3. Strategic Moves and Key Developments

Viatris significantly advanced its strategic transformation, focusing on divestitures to simplify its portfolio and targeted acquisitions to build future growth.

• Portfolio Optimization & Divestitures:
  • Biocon Biologics Stake: Viatris received $1 billion in cash in March 2024 as deferred consideration from the sale of its biosimilars business to Biocon Biologics, a transaction completed in November 2022. This move allowed Viatris to exit a non-core area and strengthen its balance sheet.
  • Women's Healthcare Business: The December 2023 sale of its Women's Health products generated $1 billion in cash proceeds, recognized in 2024. This divestiture further streamlined the company's focus.
  • Planned Divestitures: Viatris actively pursues the sale of its Over-the-Counter (OTC) business (valued at approximately $2 billion) and its Active Pharmaceutical Ingredient (API) business (valued at approximately $1 billion). The company expects to complete these planned sales by late 2025, further narrowing its focus to higher-margin specialty and complex generics.
• Strategic Acquisitions for Future Growth:
  • In March 2024, Viatris acquired certain late-stage assets from Idorsia Pharmaceuticals Ltd. for an upfront payment of $100 million, with potential future milestone payments. This acquisition brought promising new chemical entities in areas like hypertension (selatogrel) and insomnia (daridorexant), bolstering Viatris's pipeline in specialty therapeutic areas and providing potential new revenue streams post-2027. This investment in "in-process research and development" is crucial for long-term growth.

4. Financial Health and Capital Allocation

Despite revenue declines, Viatris improved its financial flexibility through strategic asset sales and disciplined capital management.

• Cash and Liquidity: Cash and cash equivalents increased significantly to $2.5 billion at year-end 2024, up from $1.0 billion in 2023, largely due to proceeds from divestitures. This provides ample liquidity for operations and strategic investments.
• Debt Management: Viatris reduced total debt from $19.0 billion in 2023 to $17.0 billion in 2024, reflecting its commitment to deleveraging using proceeds from asset sales. This reduction improves the company's debt-to-equity ratio and lowers interest expenses.
• Capital Expenditures: While physical assets saw a slight decrease in value, construction in progress increased modestly, indicating ongoing, targeted investments in manufacturing and R&D infrastructure.
• Shareholder Returns: Viatris continued its commitment to shareholder returns, repurchasing $500 million of its common stock in 2024 and maintaining its quarterly dividend, demonstrating confidence in its long-term outlook.

5. Key Risks and Challenges

Investors should be aware of several factors that could impact Viatris's future performance:

• Continued Revenue Erosion: The primary risk remains the ongoing decline in sales across both branded and generic portfolios due to patent expirations, increased competition, and pricing pressures.
• Pipeline Execution Risk: While the Idorsia acquisition adds promising assets, the success of these "in-process research and development" projects is not guaranteed and requires significant investment and regulatory approvals.
• Integration Risk: Successfully integrating newly acquired assets and divesting non-core businesses without disrupting operations requires careful execution.
• Goodwill Impairment: The 2024 net loss included significant non-cash goodwill impairment charges. This indicates that the value of some past acquisitions is not meeting original expectations, particularly in segments like Greater China, where internal assessments project a very low long-term revenue growth rate (0.5%) and a higher discount rate (10%), signaling potential future write-downs if performance does not improve.
• Regulatory and Market Pressures: The pharmaceutical industry faces constant scrutiny over drug pricing, reimbursement policies, and increasing regulatory hurdles, which can impact profitability and market access.

6. Competitive Positioning

Viatris is actively repositioning itself to enhance its competitive standing. By divesting lower-margin, highly commoditized businesses (like biosimilars, OTC, and API) and acquiring specialty assets, the company aims to:

• Focus on Higher-Value Products: Shift towards more differentiated, higher-margin specialty and complex generic products.
• Reduce Exposure to Generic Erosion: Lessen reliance on products facing intense price competition.
• Leverage Global Infrastructure: Continue to utilize its extensive global manufacturing, supply chain, and commercial infrastructure to bring new products to market efficiently.
• Build a Sustainable Pipeline: The Idorsia acquisition is a step towards building a more robust and innovative product pipeline for long-term growth.

7. Strategic Direction and Leadership

Viatris is undergoing a significant strategic transformation under its current leadership, moving from a broad-based generics and branded generics company to a more focused specialty pharmaceutical enterprise. This involves:

• Portfolio Rationalization: Systematically shedding non-core assets to simplify operations and enhance financial flexibility.
• Targeted Investments: Allocating capital to acquire assets that align with its new strategic focus and offer higher growth potential.
• Debt Reduction and Shareholder Returns: Prioritizing debt reduction and consistent shareholder returns as key components of its capital allocation strategy. This clear strategic shift aims to create a more resilient and profitable company in the long term.

8. Future Outlook

Viatris anticipates continued revenue headwinds in the near term due to ongoing divestitures and market dynamics.

• 2025 Revenue Guidance: The company projects total revenue to further decline to $12.13 billion, representing another 4.7% decrease from 2024. This projected decline is consistent across both branded and generic product categories and all geographic segments.
• Long-Term Growth: While immediate growth presents challenges, strategic investments, particularly the Idorsia assets, should contribute to new revenue streams starting in the latter half of the decade. The company aims for a return to modest growth post-2026 as its new pipeline matures and portfolio optimization concludes.
• Profitability and Cash Flow: Viatris expects to maintain strong adjusted profitability and free cash flow generation, which will be crucial for continued debt reduction and strategic investments.

9. Market Trends and Regulatory Environment

Viatris operates within a dynamic pharmaceutical landscape influenced by several key trends:

• Generic and Biosimilar Competition: Persistent pricing pressure and increased competition from new generic and biosimilar entrants continue to erode market share and profitability for established products.
• Patent Expirations: The industry faces ongoing patent cliffs for branded drugs, necessitating continuous innovation and pipeline development.
• Healthcare Policy and Reimbursement: Government and insurer efforts to control healthcare costs, including drug pricing regulations and reimbursement changes, directly impact pharmaceutical companies' revenue and margins.
• Global Economic Factors: Currency fluctuations, inflation, and geopolitical instability can affect supply chains, manufacturing costs, and sales in international markets.

Viatris's strategic pivot is a direct response to these evolving market conditions, aiming to build a business model that is more resilient to these external pressures.